VOLITIONRX LTD DL-,001 WKN: A12B6K ISIN: US9286611077 Forum: Aktien Thema: Hauptdiskussion

Die haben doch einen festen Preis bezahlt 60,1 Cent. Es sind doch nie so viele Aktien über die Börse zu den Kursen gehandelt worden. Ausserdem hat Lagoda genau den gleichen Kurs bekommen.

Kommt das aus der letzten Kapitalerhöhung als Nachkaufoption?

Sondern?

Die haben doch nicht über die Börse gekauft..

Die sind schon seit September dabei. Sah man auch am Kurs…

Armistice hat 5 Millionen investiert. Nicht schlecht.…Aber irgendwie will die Rakete nicht zünden….

https://www.gurufocus.com/news/2604881/armistice-capital-llc-acquires-new-stake-in-volitionrx-ltd

https://www.gurufocus.com/news/2604972/lagoda-investment-managements-strategic-acquisition-in-volitionrx-ltd

Sie müssen auch schnell mal Lizenzdeal für den Human-Bereich einfädeln. Sonst gibt es immer weiter Verwässerungen. Der Cash-Bestand ist ja auch nicht berauschend….

… naja. Die Tests ziehen langsam an. Das ist gut. Wenn das so weiter geht. Sie müssen die Quartalsergebnisse vervierfachen und dann wären sie Cashflow Neutral….

Sind ja eher financial lowlights…

Financial Highlights · $1 million revenue YTD 2024, up 96% over the prior YTD. · $475,000 revenue in the third quarter, up 187% over the same period in the prior year. · Nu.Q® Vet revenue up 100% YTD and 307% for the third quarter versus the same periods in 2023. · Cash used in operating activities was $5.4 million in the third quarter, down 36% YOY as cost reduction measures took effect. · Cash and cash equivalents as of September 30, 2024, totaled approximately $5.4 million. · Subsequent to quarter end received commitment of over $2.2 million of non-dilutive funding from agencies within the Walloon Region, Belgium, with more funding anticipated in quarter one 2025. · Goal to be cash neutral in 2025, meaning income matches expenditure on a cash basis.

Highlights · Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024. · Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 17 countries worldwide. · Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 and issued a report showcasing Nu.Q® NETs test data from over 3,000 intensive care sepsis patients. · Made significant progress across a number of clinical and research programs within our cancer pillar. · Advancing several active commercial discussions with significant players in the diagnostic space for both human and animal health, including large markets such as sepsis and oncology liquid biopsy. · Opened Data Rooms for potential near-term licensing opportunities. · Strengthened the Board of Directors in the appointment of experienced chair, Timothy Still and Independent Director, Dr. Ethel Rubin, both of whom bring significant commercial and financing experience in the diagnostic sector. Cameron Reynolds, President and Group Chief Executive Officer, said: “I am delighted that we have sold more than 110,000 Nu.Q® Vet Cancer Tests in the first nine months of 2024; not only is this a significant commercial achievement but means that so many families now have access to early cancer detection for their dog

Ich nehme 50% morgen mal raus…

https://qcast.page.link/EPFDnJWumwU7kEGw9

https://ir.volition.com/news-events/press-releases/detail/820/volitionrx-limited-announces-third-quarter-2024-financial-results-and-business-update